Clinical Trial Search

Primary: Incidence of Infectious Complications After Biliary Drainage — 11; 5 participants

Primary: Number of Serious Pre-operative, Operative and Post-operative Adverse Events to 120 Days Post Randomization or to 30 Days Post Surgery, Whichever Comes Last — 40; 36…

Primary: The Concentration of the Pancreatic Cancer Markers of the Normal Cohort and UICC Stage II Pancreatic Ductal Adenocarcinoma Cohort — 99097; 34095 pg/ml — p=<0.001

Primary: Papilla or Duct-enterostomy Was Reached — 10 ERCPs

Primary: Deoxyhemoglobin Concentration (DHb) — .6968475; .3483283; .7021826; .4945491 alpha units — p=0.001

Primary: Number of Participants With Any Change (2 Point Increase or Decrease) in Symptoms From Baseline — 7; 6 Participants

Primary: Number of Participants With Overall Response — 3; 12 participants

Primary: Sustained Biliary Drainage, Defined as Absence of Reinterventions for the Management of Biliary Obstructive Symptoms — 39; 43 Participants — p=<0.01

Primary: CA 19-9 Normalization — 40; 13.6; 30; 50 Percentage of participants — p=0.235

Primary: Disease Control Rate (DCR) at 4 Months Using RECIST 1.1 — 2 Participants

Primary: Late Gastrointestinal Toxicities — 13 Participants

Primary: 60-day ≥ Grade II Complication Rate — 72; 76 Participants — p=0.804

Primary: Amylase and Lipase Values in Gallbladder Bile — 5.5; 181.2; 9.5; 434.8 mg/dl

Primary: Number of Participants With Resectability Rate — 15 Participants

Primary: Assess the Occlusion Rates, Attempted Surgical Resection or Death of Plastic, Covered, and Uncovered Biliary Stents in Patients Presenting With Malignant Biliary…

Primary: Median Overall Survival of Patients With Adenocarcinoma of the Pancreas — 31.6 months

Primary: Successful Procedure Completion — 70; 5 participants

Primary: Number of Patients With Pancreatic Fistula — 9; 8 participants

Primary: Number of Subjects Completing Therapy Including Surgical Resection. — 107 Participants

Primary: Acute Toxicity Rates of Grade 3 or Greater Gastrointestinal and Hematologic Toxicities (as Raw Percentage) — 13.89; 0.00; 2.78; 0.00 percentage of participants

Primary: Time to Recurrent Biliary Obstruction — 711; 357 days — p=0.530

Primary: Response Rate — .125 proportion of participants

Primary: The Number of Participants With Response to GEMOX-Panitumumab (GEMOX-P) in Chemotherapy naïve KRAS/ BRAF Wild Type Stage IV Biliary Tract Cancer Using the Response…

Primary: S-MRCP and S-EUS Concordance

Primary: Nonfunctioning and Malignant Pancreatic Endocrine Neoplasms — 28; 12; 22; 18 participants

Primary: Progression Free Survival Rate at Five Months — 69 percentage of participants

Primary: Response Rate (RR) — 19 Participants

Primary: Overall Response Rate (ORR) — 6.9 percentage of participants

Primary: Number of Participants With Objective Response — 1 participants

Primary: Recurrence Free Survival — 15.6 months